Co-Founder
AB
Avicenna Biosciences
Avicenna Biosciences utilizes a machine learning-driven medicinal chemistry platform to optimize drug candidates by rapidly identifying new chemical entities with improved potency and selectivity. This approach addresses the high failure rates in lead optimization due to off-target toxicity and poor pharmacokinetics, significantly reducing synthetic effort and development timelines.
- Artificial Intelligence
- Data & Analytics
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$17.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$12.1M across 3 disclosed rounds
$70.7K · Undisclosed
Announced Oct 2025
Disclosed cumulative: $12.1M
3/3
Reported total $17.5M
Incomplete round history. $5.5M of the $17.5M reported total isn’t matched to a known round.
RoundDateAmountValuationInvestors
Founders
Product
Features
- Avicenna Biosciences utilizes a machine learning-driven medicinal chemistry platform to optimize drug candidates by rapidly identifying new chemical entities with improved potency and selectivity. This approach addresses the high failure rates in lead optimization due to off-target toxicity and poor pharmacokinetics, significantly reducing synthetic effort and development timelines.